Latest From MorphoSys AG
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
The latest drug development news and highlights from our US FDA Performance Tracker.
The fundamentals for Galapagos are sound despite the failure of MOR106 for atopic dermatitis and two trials of filgotinib missing their primary endpoints for Sjögren’s syndrome and lupus.
New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- MorphoSys AG
- Senior Management
Simon E Moroney, PhD, CEO
Jens Holstein, CFO
Malte Peters, MD, Chief Dev. Officer
Markus Enzelberger , PhD, CSO
- Contact Info
Phone: (49) 89 899 27 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.